Policy analysis evaluates market dynamics of generic SGLT2 inhibitors, highlighting regulatory and economic strategies to maximize drug affordability.
Key Points
To evaluate the economic, clinical, and regulatory factors influencing the market entry and adoption of generic sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Qualitative and policy analysis of drug regulatory pathways, patent exclusivity protections, and generic drug market competition for SGLT2 inhibitors.
Identified critical regulatory, payer, and legal barriers that delay the introduction and widespread uptake of first-in-class generic medications.
Highlighted policy and formulary management solutions necessary to translate generic entry into tangible cost savings for patients and health systems.